Blog

Oct 27, 2014

A Review of the Status of Biosimilars in the U.S.

The Biologics Price Competition and Innovation (BPCI) Act of 2009 was enacted as part of the Patient Protection and Affordable Care Act to establish an abbreviated pathway for the licensure by Food and Drug Administration (FDA) of biological products demonstrated to be biosimilar to or interchangeable with a FDA-licensed reference product. We at the BRIC Wall […]
back to top